Takeda's Takhzyro, an HAE prophylactic treatment acquired from Shire, receives final EMA approval.
New prophylactic therapy introduced to the European HAE market
The European Medicines Agency (EMA) has granted final approval for Takhzyro (lanadelumab), a fully human monoclonal antibody that selectively inhibits plasma kallikrein, as a prophylactic treatment for hereditary angioedema (HAE) in patients aged 12 years and older. This approval marks a significant milestone for patients in Europe, as Takhzyro is developed as a subcutaneous injection, allowing for self-administration, unlike existing treatments that typically involve intravenous injections. This is considered a regulatory achievement that will alleviate the daily burden on HAE patients who require long-term prophylactic management and significantly improve treatment adherence. Consequently, the EMA's decision represents an important step in improving access to treatment for rare disease patients in Europe.
Excellent efficacy in reducing attacks demonstrated in the Phase 3 HELP trial
The European approval of Takhzyro is based on the excellent results from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) study, which involved 125 patients over a 26-week period. In the clinical trial, patients who received Takhzyro 300 mg every two weeks showed a remarkable 87% reduction in the average number of HAE attacks compared to the placebo group. Notably, approximately 44% of patients who received active treatment remained attack-free throughout the treatment period, demonstrating a significant therapeutic benefit. This strong clinical data provided a solid medical basis for the EMA's Committee for Medicinal Products for Human Use (CHMP) to adopt a positive opinion and ultimately grant final approval.
Financial value underlying Takeda and Shire's strategic M&A
This regulatory approval serves as a key financial catalyst in the global pharmaceutical industry's mega-deal, Takeda Pharmaceutical's acquisition of Shire. Takhzyro was originally part of Shire's rare disease pipeline, acquired in 2015 through the acquisition of Dyax for a total of $6.5 billion (including an upfront payment of $5.9 billion and a CVR for an additional $646 million upon FDA approval). Subsequently, Takeda agreed to acquire Shire for approximately $62 billion, completing the deal in January 2019, and Takhzyro became a blockbuster drug representing Takeda's HAE portfolio. In other words, this European approval validates the strategic rationale for the acquisition and completes the regulatory framework for early commercial value realization.
Increasingly competitive landscape for HAE prophylactic treatments
The global HAE treatment market is estimated at approximately $3.6 billion in 2025 and continues to expand due to the demand for more convenient and effective prophylactic therapies. The existing market is dominated by C1 esterase inhibitor-based intravenous Cinryze and subcutaneous Haegarda. However, Takhzyro, with its longer half-life and convenient formulation, is expected to rapidly replace their market share. With the upcoming launch of next-generation convenience products such as BioCryst's oral prophylactic treatment Orladeyo, Takhzyro's proactive entry into the European market will be a crucial defense for Takeda to maintain its market leadership.
Takhzyro's European approval provides Takeda Pharmaceutical with an opportunity to establish a leading prophylactic pipeline in the $3.6 billion global HAE treatment market and maximize early revenue. The impressive efficacy data from the Phase 3 HELP study, with an 87% reduction in attacks and 44% of patients achieving attack-free status, will serve as a strong commercial foundation to replace existing treatments such as Cinryze and Haegarda. In the medium to long term, it will provide a first-mover advantage in the competition for market share with later entrants such as the oral drug Orladeyo, contributing to the realization of the financial value of Takeda's $62 billion acquisition of Shire. For researchers in the field of rare diseases, it will serve as a valuable reference for the development of targeted therapies by demonstrating the clinical success of a fully human monoclonal antibody that blocks plasma kallikrein. This approval will accelerate negotiations with European healthcare systems for reimbursement, serving as a short-term catalyst to rapidly increase the slope of the commercial revenue curve.
Source: EMA (ema)